[Sex hormone dependency in diffuse carcinoma of the stomach and results of chemo-endocrine therapy].
Based on experimental study that the growth of diffuse carcinoma of the stomach depended on sex hormone, chemo-endocrine therapy using an anti-estrogen after gastrectomy for female patients are carrying out in National Cancer Center Hospital since 1980. The results are as follows. The cumulative 3 year survival rate in 21 patients with chemo-endocrine therapy (TAM+) revealed significant higher (45.8%) than those (7.4%) in 23 patients with chemotherapy alone (TAM-). The results of TAM(+) in curatively resected cases (8 cases) were both 100% of 2 and 3 year survival rate with 2 recurrent cases. In TAM(-) 10 cases, 2 and 3 year survival rate showed 56.0% and 20.0% respectively (P less than 0.01). This study suggests that the chemo-endocrine therapy may be a new adjuvant therapy in female patients with diffuse carcinoma of the stomach.
D002293:Adenocarcinoma, Scirrhous / Q000032:analysis / Q000188:drug therapy*; D000368:Aged; D000818:Animals; D005260:Female; D012739:Gonadal Steroid Hormones / Q000502:physiology*; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D011944:Receptors, Androgen / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013274:Stomach Neoplasms / Q000032:analysis / Q000188:drug therapy*; D013629:Tamoxifen / Q000008:administration & dosage*; D005641:Tegafur / Q000008:administration & dosage
D012739:Gonadal Steroid Hormones; D008937:Mitomycins; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D005641:Tegafur; D016685:Mitomycin